Anakinra (Amgen) Drug Asset Due Diligence Report 2026

This Anakinra (Amgen) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

211

Registered trials

193

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Anakinra (Amgen) can convert its Interleukins profile and IL1R1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Anakinra (Amgen) (query alias: anakinra)
Modality / target	Interleukins; IL1R1; IL1R1 antagonists
Highest global status	Approved
Originator	Amgen, Inc.
Active developers	Swedish Orphan Biovitrum AB, Swedish Orphan Biovitrum Pty Ltd., Supi Pharmaceutical (Shanghai) Co., Ltd.

The MCP disease footprint includes Deficiency of Interleukin-1 Receptor Antagonist, COVID-19, Cryopyrin-Associated Periodic Syndromes. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07580079	Phase 2	Not yet recruiting	1	Mean Amplitude of Sensor Glucose Excursions (MAGE) during Anakinra treatment compared to placebo
NCT07503834	Phase 1/2	Not yet recruiting	15	evaluate the safety of IL-1β in a pilot study of patients who have undergone a pancreas transplant
NCT07600190	Phase 1	Not yet recruiting	60	Effect of Anakinra on absolute change in morning PEF from baseline during moderate asthma exacerbation

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

DOES LONG-TERM ANAKINRA TREATMENT INCREASE THE RISK OF INFECTIONS AND TUBERCULOSIS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER?

Not Applicable; n=30; evaluation: Positive. Reported fields: Antibiotic use = 56.0 course

LONG-TERM REAL-WORLD OUTCOMES OF ANAKINRA IN SCHNITZLER SYNDROME: BIOMARKER DISCRIMINATION, WEIGHT GAIN AND DOSE TAPERING IN A POLISH COHORT

Not Applicable; n=13; evaluation: Positive. Reported fields: CRp = 0.5 mg/L

OUTCOMES OF PATIENTS WITH HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) IN QUEEN ELIZABETH HOSPITAL, BIRMINGHAM: A SERVICE EVALUATION

Not Applicable; n=76; evaluation: Positive. Reported fields: -; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Anakinra (Amgen) addresses Deficiency of Interleukin-1 Receptor Antagonist, COVID-19, Cryopyrin-Associated Periodic Syndromes. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Interleukins—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-01-29	Acino signs an exclusive distribution agreement with the Swedish biopharmaceutical company Sobi in Kazakhstan	Approved	Financial terms not disclosed
2022-03-29	SelectImmune Pharma is chosen to develop Sobi's Kineret for treating specific forms of cystitis and bladder pain syndrome in patients.	Approved	Financial terms not disclosed
2008-12-16	Biovitrum and Amgen Announce Close of Product Acquisition Deal	Approved	US$13.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “New therapeutic use of anakinra for covid-19”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO